Nimesulide Φαρμασυν

Nimesulide, the active ingredient in Nimesulide Φαρμασυν, is a nonsteroidal anti-inflammatory drug (NSAID) presented as a topical formulation for cutaneous use. It is employed to relieve pain, reduce inflammation, and lower fever in adult patients requiring short‑term therapy.

GNH USA supplies Nimesulide Φαρμασυν as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under strict Good Manufacturing Practice guidelines.

Nimesulide is an NSAID that alleviates symptoms by inhibiting cyclooxygenase‑2 mediated prostaglandin production.

Pain: provides analgesic relief for mild to moderate acute pain. Inflammation: reduces swelling and discomfort in musculoskeletal inflammatory conditions. Fever: lowers elevated body temperature in febrile episodes.

Nimesulide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Skin irritation at the application site. - Itching or pruritus. - Headache. - Dizziness.

Serious or Rare Side Effects: - Hepatic enzyme elevation or hepatitis. - Severe skin reactions such as Stevens‑Johnson syndrome. - Gastrointestinal ulceration or bleeding. - Renal impairment or failure.

When prescribing Nimesulide, clinicians should consider several safety precautions to minimize risk.

Assess liver function: monitor hepatic enzymes before and during treatment. Evaluate renal function: adjust use in patients with renal impairment. Avoid in known hypersensitivity to NSAIDs: discontinue if allergic reaction occurs. Use lowest effective dose for the shortest duration: limit exposure to reduce adverse events. Store at ambient temperature: keep in original container, protect from moisture and light.

Nimesulide can interact with other medicines, necessitating careful review of a patient’s medication list.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: elevated lithium serum concentrations. - Methotrexate: enhanced methotrexate toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible decline in renal function. - Diuretics: reduced diuretic efficacy and risk of electrolyte imbalance. - SSRIs or SNRIs: heightened bleeding tendency.